AIM OF THE STUDY: @entity344 is the most common type of @entity706 and commonly involved site is the stomach. We have compared the superiority between treatment modalities for primary @entity6595 and we want to investigate efficacy of rituximab in @entity6595 . MATERIAL AND METHODS: Between April 2002 and December 2011, 146 @entity1 with a histologically confirmed primary @entity6595 , initially diagnosed at eight different @entity5 Centers within @entity233 were evaluated retrospectively. According to the treatment modality, the @entity1 were divided into chemotherapy (CT) alone, chemotherapy and radiotherapy (CRT), @entity1104 ( @entity1104 ), surgery along with chemotherapy and radiotherapy ( @entity12818 ), and surgery (S) alone groups. RESULTS: Median follow-up period was 25.5 months. The 5-year EFS (event free survival) and @entity1349 ( @entity1349 ) rates for the @entity1 were 55% and 62.3% respectively. In Log rank analysis of @entity1349 and EFS, we have identified levels of albumin and hemoglobine, IPI score, stage at diagnosis as factors influencing survival. In multivariate analysis of @entity1349 and EFS, only albumin and stage at diagnosis were factors independently contributing to survival. There was no statistically significant difference in terms of survival between different treatment modalities (p = 0.707 in EFS and p = 0.124 in @entity1349 ). In analysis of @entity1 treated with chemotherapy alone, there was no a statistically significant difference in terms of EFS and @entity1349 between chemotherapy regimens with or without rituximab in localized and advanced stage groups (p = 0.264 and p = 0.639). There was no statistical difference in survival rate (EFS and @entity1349 ) between surgical or non-surgical treatment modalities for localized/advanced stage @entity6595 groups (p = 0.519 / p = 0.165). CONCLUSIONS: There are several treatment options due to similar results in different treatment modalities. Also benefit of rituximab treatment in @entity6595 is still a controversial subject. Additional prospective trials are definitely required in order to clarify use of rituximab in treatment of extranodal @entity6595 .

Treatment modalities in primary XXXX : the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity706 :: ('MESH:D008223', 'Disease') :: ['extranodal lymphoma'] @entity6595 :: ('MESH:C535648', 'Disease') :: ['gastric lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity233 :: ('9103', 'Species') :: ['Turkey'] @entity344 :: ('MESH:D005767', 'Disease') :: ['Gastrointestinal lymphoma'] @entity12818 :: ('83482', 'Gene') :: ['SCRT'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['surgery and chemotherapy', 'SCT'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity6595 :: (MESH:C535648,Disease) :: ['gastric lymphoma']
